Information Journal Paper
APA:
Copy. (2018). KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. JOURNAL OF CYSTIC FIBROSIS, 17(4), 484-491. SID. https://sid.ir/paper/757074/en
Vancouver:
Copy. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. JOURNAL OF CYSTIC FIBROSIS[Internet]. 2018;17(4):484-491. Available from: https://sid.ir/paper/757074/en
IEEE:
Copy, “KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa,” JOURNAL OF CYSTIC FIBROSIS, vol. 17, no. 4, pp. 484–491, 2018, [Online]. Available: https://sid.ir/paper/757074/en